• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 5. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Benzimidazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles

Professional Introduction to 2-(1-chloroethyl)-1H-benzimidazole (CAS No. 19275-82-2)

2-(1-chloroethyl)-1H-benzimidazole, identified by the Chemical Abstracts Service Number (CAS No.) 19275-82-2, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry. This compound belongs to the benzimidazole class, a structural motif renowned for its broad spectrum of biological activities. The presence of a chloroethyl substituent at the 2-position introduces unique reactivity and functional properties, making it a valuable scaffold for drug discovery and development.

The benzimidazole core is a privileged structure in medicinal chemistry, exhibiting diverse pharmacological effects ranging from antiviral and anticancer to anti-inflammatory and antimicrobial properties. The introduction of the 1-chloroethyl group at the 2-position of the benzimidazole ring enhances its potential as a bioactive molecule by introducing electrophilic centers that can participate in nucleophilic substitution reactions. This modification allows for further derivatization, enabling the exploration of novel analogs with tailored biological profiles.

Recent advancements in the synthesis and application of 2-(1-chloroethyl)-1H-benzimidazole have highlighted its utility in preclinical studies. Researchers have demonstrated its efficacy in modulating signaling pathways associated with cancer progression. Specifically, studies have indicated that this compound can interfere with key enzymes involved in tumor growth and metastasis, such as kinases and phosphodiesterases. The 1-chloroethyl moiety plays a crucial role in these interactions by facilitating covalent binding to target proteins, leading to prolonged inhibition of pathological pathways.

In addition to its oncological potential, 2-(1-chloroethyl)-1H-benzimidazole has shown promise in addressing inflammatory disorders. Emerging research suggests that this compound can modulate immune responses by interacting with specific receptors on immune cells. The benzimidazole scaffold is known to exhibit immunomodulatory effects, and the 1-chloroethyl group further enhances its ability to engage with biological targets. Preclinical data indicate that this compound may serve as a lead candidate for developing novel therapeutics targeting autoimmune diseases and chronic inflammation.

The synthetic chemistry of 2-(1-chloroethyl)-1H-benzimidazole has been refined to achieve high yields and purity, making it accessible for further structural optimization. Modern synthetic approaches leverage transition metal catalysis and palladium-mediated cross-coupling reactions to construct the benzimidazole core efficiently. The introduction of the 1-chloroethyl group is typically achieved through nucleophilic substitution reactions, where chloroethanol or related derivatives are used as starting materials. These synthetic strategies ensure that the final product is suitable for downstream applications in drug development.

One of the most compelling aspects of 2-(1-chloroethyl)-1H-benzimidazole is its versatility as a pharmacophore. The combination of the benzimidazole ring and the 1-chloroethyl substituent creates multiple sites for functionalization, allowing chemists to explore a wide range of analogs with distinct pharmacological properties. Computational modeling and high-throughput screening have been employed to identify derivatives with enhanced potency and selectivity. These computational tools help predict binding affinities and optimize molecular interactions, accelerating the drug discovery process.

The pharmacokinetic profile of 2-(1-chloroethyl)-1H-benzimidazole has been evaluated in preclinical models to assess its bioavailability and metabolic stability. Studies indicate that this compound exhibits reasonable oral absorption and distributes widely throughout the body, suggesting potential for systemic therapeutic action. Additionally, preliminary data on its metabolic fate reveal that it undergoes biotransformation via cytochrome P450 enzymes, which is critical for understanding its safety profile and potential drug-drug interactions.

Future directions in the research of 2-(1-chloroethyl)-1H-benzimidazole include exploring its role in targeted therapy strategies. The ability to conjugate this compound with targeting ligands or imaging agents opens up possibilities for applications in precision medicine. For instance, radiolabeled derivatives could be used for positron emission tomography (PET) imaging, enabling non-invasive monitoring of disease progression and treatment response. Such applications would significantly enhance diagnostic capabilities in oncology and other therapeutic areas.

The growing interest in 2-(1-chloroethyl)-1H-benzimidazole underscores its importance as a chemical entity with multifaceted applications in pharmaceutical research. As our understanding of molecular interactions continues to evolve, this compound will likely remain at the forefront of drug discovery efforts. Its unique structural features and biological activities make it a compelling candidate for developing next-generation therapeutics aimed at treating complex diseases.

In conclusion, 2-(1-chloroethyl)-1H-benzimidazole (CAS No. 19275-82-2) represents a significant advancement in medicinal chemistry due to its versatile biological activities and synthetic accessibility. Ongoing research continues to uncover new therapeutic potentials for this compound, positioning it as a cornerstone in the development of innovative treatments for cancer, inflammation, and other challenging medical conditions.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)